Mira Kyivska

Why is Ionis Pharmaceuticals stock up 3% today?

Why is Ionis Pharmaceuticals stock up 3% today?
Ionis pharmaceuticals rises 3.03% today

Ionis Pharmaceuticals, Inc. (IONS) is up 3.03% today as buyers respond to ongoing momentum after the company received EU approval for its RNA-targeted therapy Tryngolza (olezarsen) to treat severe hypertriglyceridemia. The rebound looks limited, with Ionis Pharmaceuticals still trading below the 20-day, 50-day, and 200-day moving averages.

IONS price prediction
24H 0.95%
$27.65
48H 1.64%
$27.84
7D 1.57%
$27.82
1M -50.6%
$13.53
3M -46.55%
$14.64
6M -49.58%
$13.81
12M -70.46%
$8.09
Current price: $27.39 0.4650 1.73%
Closed 11/18
Daily range 26.70 Arrow from to Icon 28.04
Weekly range 26.55 Arrow from to Icon 29.90
Loading...

Highlights

  • Ionis Pharmaceuticals received EU approval for Tryngolza in severe hypertriglyceridemia, with a label expansion set for November 2026.
  • Third-quarter revenues for Tryngolza missed estimates and Ionis lowered its sales guidance, with multiple law firms announcing investor investigations.
  • Ionis Pharmaceuticals stock trades below key moving averages, with technical indicators showing pronounced weakness and a 78% probability of a move to $26.08 to $29.4 over the next five days.

Muted investor confidence as sales miss triggers regulatory scrutiny

Ionis Pharmaceuticals received EU approval for Tryngolza (olezarsen) in adults with severe hypertriglyceridemia, with the European Commission granting a label expansion in November 2026. The company reported third-quarter revenues for Tryngolza that fell short of expectations, which led Ionis to lower its sales guidance for the drug. Law firms, including Bronstein, Gewirtz & Grossman, announced investigations into Ionis Pharmaceuticals on behalf of investors. The company also highlighted ongoing launches of three new medicines at the Jefferies Global Healthcare Conference, confirming that it now has seven products on the market for eight disease indications.

Anton Kharitonov, expert at Traders Union, sees Ionis Pharmaceuticals facing prolonged downside pressure despite the temporary rebound from EU approval news. He notes the stock is trading below all key moving averages, which, combined with weak revenue data and ongoing legal scrutiny, suggests poor technical and fundamental health. Oversold indicators highlight investor pessimism rather than signaling a turn. Kharitonov warns that negative momentum and unresolved investigations may keep the stock under pressure. "Short-term rallies could be sold into — I view the current recovery as lacking real conviction given the pronounced technical and legal headwinds."
Viktoras Karapetjanc, expert at Traders Union, focuses on Ionis Pharmaceuticals’ expansion potential after the EU’s green light for Tryngolza. He highlights the company’s growing portfolio, now featuring seven marketed products for eight indications, and views recent approvals as positioning Ionis for future sales growth. Despite a temporary downgrade in guidance, he notes that continued regulatory progress and product launches reflect promising fundamentals. Karapetjanc sees the current pullback as an opportunity for patient investors. "With robust pipeline momentum and new regulatory wins, I expect further growth — the market offers a bullish setup above $29.4 if momentum shifts."
Sholanke Dele, market strategist, points to a fragile sentiment backdrop for Ionis Pharmaceuticals. He underscores the lack of investor confidence, noting that law firm investigations and missed revenue targets have forced guidance reductions. Dele believes that persistent seller dominance and weak technicals make a sustained rally unlikely. "Despite the recent news, I do not see the market rewarding Ionis meaningfully in the near term — negative flows and legal risks outweigh the current optimism."
Ionis Pharmaceuticals asset chart
Ionis Pharmaceuticals price dynamics. Source: TradingView.

Persistent selling pressure as momentum indicators confirm broad weakness

Ionis Pharmaceuticals is trading below the 20-day, 50-day, and 200-day moving averages ($37.51, $42.47, and $63.95), indicating persistent downside pressure from sellers in short, medium, and long-term views. The nearest resistance is at $29.4, with today’s high at $27.68 acting as the closest support; the moving average alignment confirms a broadly bearish long-term trend. Momentum indicators signal pronounced weakness: MACD and Average Directional Index (ADX) both favor continued selling pressure. Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) each register in their oversold zones, suggesting the stock is at an extreme that may precede a potential technical rebound but does not guarantee one. Sellers currently dominate intraday momentum according to Bull/Bear Power (BBP), with the Awesome Oscillator neutral. Intraday volatility stands at 3.67%, reflecting strength toward session highs despite momentum indicators remaining bearish overall.

Earlier, analysts noted that Ionis Pharmaceuticals was experiencing persistent bearish momentum, with technical indicators and price action emphasizing continued downside risk. The current setup strengthens that outlook, with sustained selling pressure and recent volatility underscoring $29.4 as a key resistance level that traders should monitor closely for signs of a potential technical rebound or renewed decline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.